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Abstract
Purpose For the quantification of cardiac
123I-metaiodo-
benzylguanidine (MIBG) uptake, the mediastinum is
commonly used as a reference region reflecting nonspecific
background activity. However, variations in the quantity of
vascular structures in the mediastinum and the rate of renal
clearance of
123I-MIBG from the blood pool may contribute
to increased interindividual variation in uptake. This study
examined the relationship between changes in heart (H) and
mediastinal (M) counts and the change in vascular
123I-
MIBG activity, including the effect of renal function.
Methods Fifty-one subjects with ischemic heart disease
underwent early (15 min) and late (4 h) anterior planar
images of the chest following injection of
123I-MIBG.
Vascular
123I-MIBG activity was determined from venous
blood samples obtained at 2 min, 15 min, 35 min, and 4 h
post-injection. From the vascular clearance curve of each
subject, the mean blood counts/min per ml at the time of
each acquisition and the slope of the clearance curve were
determined. Renal function was expressed as the estimated
creatinine clearance (e-CC) and the estimated glomerular
filtration rate (e-GFR). Relations between H and M region
of interest (ROI) counts/pixel, vascular activity, and renal
function were then examined using linear regression.
Results Changes in ROI activity ratios between early and
late planar images could not be explained by blood activity,
the slope of the vascular clearance curves, or estimates of
renal function. At most 3% of the variation in image counts
could be explained by changes in vascular activity (p=
0.104). The e-CC and e-GFR could at best explain
approximately 1.5% of the variation in the slopes of the
vascular clearance curve (p=0.194).
Conclusion The change in measured H and M counts
between early and late planar
123I-MIBG images is
unrelated to intravascular levels of the radiopharmaceutical.
This suggests that changes in M counts are primarily due to
decrease in soft tissue activity and scatter from the adjacent
lungs.
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Introduction
The myocardial sympathetic nervous system is activated in
patients with heart failure (HF) and this activation has been
shown to be associated with increased mortality [1].
Cardiac sympathetic hyperactivity can be scintigraphically
visualized by
123I-metaiodobenzylguanidine (MIBG), a
radiolabeled analogue of noradrenalin. This noninvasive
technique has been demonstrated to be a powerful
prognostic marker in HF patients [2–4].
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123I-MIBG imaging, the most commonly
used quantitative parameters are the heart to mediastinum
(H/M) ratio and washout (WO) determined from planar
images. The H/M is a measure of specific to nonspecific
uptake, while the WO is a measure of neuronal integrity. A
basic assumption associated with use of the mediastinum as a
reference for H/M and WO calculations is that the counts in
this region represent nonspecific binding of the radioligand.
One potential confounder for assessment of nonspecific
123I-MIBG background activity is residual tracer in the
blood. Since the mediastinum contains a relatively large
volume of vascular structures, intravascular
123I-MIBG
activity may contribute to total mediastinal activity which
may influence the quantification of the H/M ratio. Since the
clearance rate of
123I-MIBG from the blood is largely
dependent on renal function [5, 6], and renal dysfunction is
often present in HF patients, differences in the rate of
vascular clearance may also contribute to increased inter-
individual variation in uptake quantification [7, 8].
The objective of this study was to assess the magnitude
of the influence of residual vascular
123I-MIBG activity on
image quantification by examining the relationship between
changes in vascular activity and changes in heart (H) and
mediastinal (M) activity between early and late planar
123I-
MIBG images.
Materials and methods
As part of a prospective multicenter trial [9], 51 subjects (48
male, 3 female; mean age 65.2) with ischemic heart disease
(history of ≥ 1 myocardial infarction) underwent myocardial
123I-MIBG imaging. The study protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by each institution's human
research committee. All subjects signed informed consent
before performance of any study procedure.
Imaging procedures
All subjects received 370 MBq (10 mCi;±10%) of
123I-
MIBG (AdreView™, GE Healthcare) and underwent 10-min
planar images of the anterior thorax at 15 min (early; e) and
4 h (late; l) post-injection (p.i.). The images were acquired
with a 20% energy window centered at 159 keV, low-energy
high-resolution (LEHR) collimation, and stored in a 128×
Fig. 1 The upper panels show an example of the planar
123I-MIBG
images of a male subject (age 58 years, NYHA III, LVEF 36%) with a
history of a previous myocardial infarction. The upper panel on the
left displays the image at 15 min p.i. (early) and the upper panel on
the right shows the image at 4 h p.i. (late). The lower panels display
the positioning of the ROIs on the early (lower left) and late (lower
right) planar images. The positioning of the mediastinal ROI was
standardized in relation to the lung apex and the midline between the
lungs. In this example the early H/M was 1.54, the late H/M 1.40, and
myocardial WO 9%
Eur J Nucl Med Mol Imaging (2011) 38:1132–1138 1133128 matrix. All digital image files were sent to an Imaging
Core Laboratory (ICL) for evaluation and analysis.
Image analysis
An experienced nuclear medicine technologist processed all
the planar images to determine the H and M count densities.
The heart region of interest (ROI) was drawn manually to
include both ventricles and any atrial activity that was clearly
visible. A 7×7 pixel squaremediastinal ROI was drawn in the
upper mediastinum, using the apices of the lungs as anatomic
landmarks(Fig.1). Activity per ROI (mean counts/pixel) was
corrected for decay to the time of injection and expressed as
activity in the myocardium and mediastinum at 15 min and
4hp . i .( H e,H l,H l/He,M e,M l,a n dM l/Me). In addition,
commonly used semiquantitative
123I-MIBG myocardial
parameters were assessed to better describe the clinical
condition of the subjects. Early (15 min p.i.) and late
(4 h p.i.) H/M ratios were calculated as the ratios of the mean
counts per pixel in the two ROIs. All images and ROIs were
reviewed by three independent readers, and a single
aggregate H/M was derived for each image, either the value
accepted by at least two readers, or if this criterion was not
satisfied, the average H/M for all readers [9]. In addition,
myocardial WO was calculated as:
early H=M   late H=M ðÞ
early H=M

  100%
Vascular activity
Blood samples (2 ml) were taken at 2 min, 15 min, 35 min,
a n d4hp . i .S u b s e q u e n t l y ,1 - m la l i q u o t sw e r ec o u n t e di na
well counter (energy peak at 159 keV with a 15% energy
window). Activity (counts/min) was corrected for decay to
the time of injection. For each patient a vascular clearance
curve was plotted. Figure 2 shows a typical example with
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Fig. 3 Scatter plot showing the blood activity in relation to time for
all subjects
Table 1 Demographic and cardiac medical history information for the
51 subjects included in the study
Baseline characteristics
Male/female 48/3 (94/6%)
Age (years) 65.3±9.1 (42–84)
NYHA (I/II/III) 4/28/11 (8/55/22%)
ACC/AHA HF class (B/C) 15/36 (29/71%)
LVEF 33±8 (15–48)
Medication
Beta-blockers 45 (88%)
ACE inhibitor/AT-II receptor blockers 46 (90%)
Aldactone 16 (32%)
Amiodarone 10 (20%)
Calcium channel blocker 12 (24%)
Estimates of renal function
Creatinine (μmol/l) 113.4±42.4 (59–296)
e-CC (ml/min) 74.8±29.2 (19.9–156.9)
e-GFR (ml/min per 1.73m
2) 66.2±21.4 (19.1–125.6)
Semiquantitative
123I-MIBG parameters
Early H/M 1.51±0.25 (0.60–1.99)
Late H/M 1.44±0.18 (1.05–1.96)
Myocardial WO (%) 8.2±6.8 (5.3–10.8)
Data are expressed as mean ± SD and range or as absolute numbers
and percentage
NYHA New York Heart Association functional classification, LVEF
left ventricular ejection fraction, ACC/AHA HF class American
College of Cardiology and American Heart Association classification
of HF, e-CC estimated creatinine clearance calculated using the
Cockcroft-Gault equation, e-GFR estimated glomerular filtration rate
calculated using the abbreviated Modification of Diet in Renal Disease
(MDRD) equation
0
Time(min)
Activity (counts/min/ml)
T1 2 TT 3 T 4
C4
C3
C2
C1
Fast slope = (C2-C1)/(T2-T1)
Slow slope = (C4-C3)/(T4-T3)
Fig. 2 In this typical example of a blood activity clearance curve,
there is a clear distinction between a more accelerated phase and a
slower phase. The slopes of both the faster (Sf) and slower (Ss) phases
were calculated as illustrated in the figure
1134 Eur J Nucl Med Mol Imaging (2011) 38:1132–1138two distinct phases, an accelerated clearance followed by a
slower clearance. The slopes of the two phases of the
clearance curves were determined according to biexponential
curve fitting [accelerated phase (Sf)a n dt h es l o w e rp h a s e
(Ss), expressed as cpm/ml per min].
Based upon the vascular clearance curve, the mean
activity (cpm/ml) was calculated for the time intervals
during which the two planar images were acquired (15–
25 min and 3 h 50 min–4 h p.i.: Ve and Vl). The ratio of Ve
and Vl and the ratio between the slopes of the accelerated
phase (Sf) and the slower phase (Ss) of the blood clearance
were then calculated.
Determination of renal function
Serum concentrations of creatinine were determined from
blood samples obtained as part of screening evaluations
performed within 7 days prior to
123I-MIBG imaging.
Analyses were performed at a central laboratory, with
reference ranges of 75–111 μmol/l for men and 53–
106 μmol/l for women.
Renal function was estimated using two methods.
Estimated creatinine clearance (e-CC) was calculated (in
ml/min) using the Cockcroft-Gault equation [10]:
e   CC ¼
140   age years ðÞ ½  ðÞ   weight kg ðÞ ½ 
serum creatinine mmol=L ðÞ ½ 
  1:04 for females and 1:23 for males ðÞ
Estimated glomerular filtration rate (e-GFR) was calcu-
lated using the abbreviated Modification of Diet in Renal
Disease (MDRD) equation [11]:
e   GFR ¼ 32788   serum creatinine mmol=L ðÞ ½ 
 1:154
  age years ðÞ ½ 
 0:203   0:742 for females ½ 
  1:212 for blacks ½ 
e-GFR was expressed per 1.73 m
2 of body surface area
(ml/min per 1.73 m
2). According to the guidelines for
identification, management, and referral of adults with
chronic kidney disease, patients were stratified as having
impaired kidney function [e-CC or e-GFR < 60 ml/min(per
1.73 m
2)] or normal function {e-CC or e-GFR [≥ 60 ml/min
(per 1.73 m
2)]} [12].
Statistical analysis
Linear regression was used to examine the relationships
between the vascular activity ratio (Vl/Ve), the slope of the
vascular clearance curve (Sf/Ss), and the scintigraphically
determined activity in the myocardium and mediastinum at
15 min and 4 h p.i. (He,H l,H l/He,M e,M l, and Ml/Me). The
overall goodness-of-fit was expressed as the adjusted R
2.
The F test was used to assess whether the analysis
explained a significant proportion of the variability. A p<
0.05 was considered to indicate a statistically significant
difference. A significant adjusted R
2 would indicate that
variation in the scintigraphically determined parameters
could be explained by a percentage (adjusted R
2) of change
in vascular activity. All statistical analyses were performed
with SPSS (SPSS for Windows, version 17.0.2, SPSS Inc.,
Chicago, IL, USA).
Results
Demographic and cardiac medical history information
for the 51 subjects included in the study is summarized
in Table 1. The majority of patients was male, had New
York Heart Association (NYHA) class II HF, and had
left ventricular ejection fraction (LVEF) < 40%. Eight
patients had no history of HF. The majority of subjects
were on a combination of beta-adrenergic receptor
blockers and angiotensin-converting enzyme (ACE)
Fast part Slow part Ratio fast vs slow
Slope of clearance curve (counts/min) −0.166±0.083 −0.003±0.001 63.11±45.00
(−0.353 to −0.034) (−0.007 to −0.001) (13.71–227.12)
Table 2 Slope of blood activity
clearance curve (biexponential
curve fitting)
Data are expressed as mean ±
SD and range
Early (15 min) Late (240 min) Ratio late vs early
Intravascular activity (counts/min/ml) 93,379±65,841 31,702±23,298 0.35±0.11
(10,074–322,169) (3,568–162,250) (0.13–0.65)
Myocardial activity (counts/min) 97±41 61±27 0.63±0.08
(28–185) (17–132) (0.47–1.05)
Mediastinal activity (counts/min) 64±28 43±20 0.67±0.09
(21–115) (13–82) (0.48–1.15)
Table 3 Intravascular and
imaging parameters
Data are expressed as mean ±
SD and range
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(Table 1).
Estimates of renal function showed a substantial varia-
tion (Table 1). In 26 (51%) patients creatinine levels were
above the normal limit (25 men and 1 woman). Calculated
e-CC was < 60 ml/min in 19 (38%) patients and the
calculated e-GFR was < 60 ml/min per 1.73 m
2 in 24 (47%)
patients.
There was a considerable range in the initial (i.e., fast)
part of the
123I-MIBG vascular clearance curves (Fig. 3).
Despite this individual variation, the mean Sf was more
than 60 times steeper compared to the mean Ss (Table 2).
Mean intravascular activity (cpm/ml) decreased approxi-
mately 65% between 15 min and 4 h p.i. (Table 3). The
mean scintigraphically determined myocardial and medias-
tinal activity (counts/min) decreased approximately 37 and
33%, respectively, between 15 min and 4 h p.i. (Table 3).
Variation in any of the scintigraphic parameters (Me,M l,
Ml/Me,H e,H l,a n dH l/He) could not be explained by
intravascular activity (Table 4). At most the counts in the
blood at 15 min (Ve) could explain approximately 3% of the
variation in the mediastinal counts at 15 min (Me)( p=
0.120). Variation of the scintigraphic parameters could also
not be explained by the slope of the clearance curves
(Table 5). The slope of the clearance curves could at best
explain up to 3% of the variation in the mediastinal counts
(Me vs Sf and Ml vs Ss, p=0.105 and p=0.100,respectively).
The variability in the change of intravascular activity (Sf,
Ss, and Sf/Ss) could not be explained by either estimate of
renal function (e-CC or e-GFR) (Table 6). The e-CC could
at best explain approximately 1.5% of the variation in the
fast slope of the vascular clearance curve (e-CC vs Sf,
p=0.194).
Discussion
Most in vivo scintigraphic quantification of regional
neurotransporter activity or receptor density involves
comparison of uptake in a target ROI to that in a reference
region of nonspecific uptake/binding. For assessment of
sympathetic myocardial activity with
123I-MIBG scintigra-
phy, use of the mediastinum as a reference region is based
on the assumption that there is a negligible amount of
specific uptake of
123I-MIBG in this region. In addition,
presence of
123I-MIBG in the blood pool is also assumed to
be insignificant. The present results demonstrate that
changes in blood pool/vascular
123I-MIBG activity do not
significantly correlate with changes in heart and mediasti-
num activity between early and late planar images. This is
Table 4 Variability of scintigraphic parameters in relation to intravascular activity (linear regression)
Constant SE c Coefficient b SE b Adjusted R
2 p value
Me vs Ve 564.2 64.8 0.001 0.001 0.028 0.120
Ml vs Vl 430.2 45.8 0.001 0.001 0.001 0.905
Ml/Me vs Vl/Ve 0.67 0.05 0.014 0.122 0.006 0.912
He vs Ve 878.4 97.3 0.001 0.001 0.014 0.191
Hl vs Vl 602.8 63.2 0.001 0.002 0.001 0.822
Hl/He vs Vl/Ve 0.59 0.04 0.126 0.109 0.01 0.253
SE standard error, Me scintigraphically determined mediastinal counts 15 min p.i. (early), Ml scintigraphically determined mediastinal counts 4 h
p.i. (late), He scintigraphically determined myocardial counts 15 min p.i. (early), Hl scintigraphically determined myocardial counts 4 h p.i. (late),
Ve intravascular radioactivity 15 min p.i. (early), Vl intravascular radioactivity 4 h p.i. (late)
Table 5 Variability of scintigraphic parameters in relation to the slopes of the blood activity clearance curve (linear regression)
Constant SE c Coefficient b SE b Adjusted R
2 p value
Me vs Sf 532.9 83.3 −738.779 447.576 0.033 0.105
Ml vs Ss 542.0 69.4 33,361 19,957 0.032 0.100
Ml/Me vs Ss/Sf 0.670 0.022 4.44 10
−5 0.022 0.001 0.875
He vs Sf −0.127 0.031 −3.99 10
−7 −0.192 0.018 0.172
Hl vs Ss 0.004 0.000 8.98 10
−7 0.000 0.016 0.177
Hl/He vs Ss/Sf 0.631 0.020 −2.21 10
−7 0.000 0.001 0.999
SE standard error, Me scintigraphically determined mediastinal counts 15 min p.i. (early), M l scintigraphically determined mediastinal counts 4 h
p.i. (late), He scintigraphically determined myocardial counts 15 min p.i. (early), Hl scintigraphically determined myocardial counts 4 h p.i. (late),
Sf slope of the accelerated (fast: f) part of the blood activity clearance curve, Ss slope of the slower (s) part of blood activity clearance curve
1136 Eur J Nucl Med Mol Imaging (2011) 38:1132–1138consistent with rapid clearance of
123I-MIBG from the
blood and uptake into organs (such as the heart) by means
of the norepinephrine transporter.
As intravascular activity appears to play no role in the
variation of the counts measured in the mediastinum, those
counts likely reflect a combination of mediastinal tissue
activity and scatter from
123I-MIBG in adjacent organs
(e.g., liver, lungs) [13]. This shows that for routine
quantification, the mediastinum is acceptable as a reference
region. However, these findings do not confirm that the
mediastinum represents a background region with only
nonspecific uptake/binding. To test this hypothesis would
require a study where the specific uptake of
123I-MIBG via
the presynaptic norepinephrine transporter (i.e., uptake 1)
was blocked and compared to a similar study without
blocking. To our knowledge this type of study has not been
performed in humans.
In subjects with normal renal function, intravenously
administered
123I-MIBG is almost exclusively excreted via
the kidneys within 24 h after injection, with approximately
35% of administered
123I-MIBG already excreted by 6 h [5,
6]. There are complex interactions between sympathetic
regulation of renal function and cardiac function. For
example, increased sympathetic activity reduces the filtration
fraction [14, 15]. In addition, renal dysfunction is often
present in HF patients, which may further increase the
interindividual variation of blood pool clearance [7, 8].
Moreover, as a reduced GFR is associated with a reduced
blood clearance of
123I-MIBG, the excretion of
123I-MIBG is
not only dependent on filtration but also by tubular secretion
[16]. In the present study, although approximately 40% of
the patients had decreased renal function, differences in the
rate of renal excretion did not contribute to variability in the
mediastinal and myocardial
123I-MIBG uptake. Therefore,
within the typical time frame of
123I-MIBG cardiac imaging
(up to 4 h after injection),
123I-MIBG mediastinal and
myocardial activity determinations appear independent of
the rate of blood clearance via the kidneys.
Radioactivity as measured in the blood samples may be in
part explained by
123I not bound to MIBG and this may have
influenced our results. However, according to specifications of
the manufacturer the radiochemical purity of the
123I-MIBG
used prior to injection is always more than 97% and in clinical
practice the fraction of free
123I does not exceed 2%. Secondly,
after intravenous administration,
123I - M I B Gi nh u m a n si sv e r y
s t a b l ea n dn o ts u b j e c tt oi nv i v od e i o d i n a t i o n[ 17]. In addition,
the clearance rate of both
123I-MIBG and free
123If r o mt h e
blood pool is rapid and is almost exclusively dependent on
renal excretion. Therefore, the impact of free
123Io nt h e
present results should be negligible.
In conclusion, in patients with ischemic heart disease,
due to rapid clearance of
123I-MIBG from the blood, the
heart and mediastinal count densities measured on
planar
123I-MIBG images at 15 min and 4 h are not
affected by residual vascular activity. In addition, this
observation holds for the broad range of renal function
commonly encountered in heart disease patients. Therefore,
no correction for blood pool activity or renal function is
needed for the calculation of myocardial WO. However, the
clinical appropriateness of using mediastinal activity as a
background correction in such calculations, which depend
on the assumption that there is no specific uptake/binding
in this region, remains to be demonstrated.
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Table 6 Variability of estimates of renal function in relation to the slopes of the blood activity clearance curve (linear regression)
Constant SE c Coefficient b SE b Adjusted R
2 p value
e-CC vs Sf 62.9 8.4 −59.3 45.1 0.014 0.194
e-CC vs Ss 63.6 10.3 −3,470.1 2,953.7 0.007 0.245
e-CC vs Sf/Ss 69.9 6.5 0.052 0.084 −0.012 0.536
e-GFR vs Sf 63.5 6.3 −11.0 33.8 −0.017 0.746
e-GFR vs Ss 63.2 7.6 −947.9 2,158.8 −0.015 0.666
e-GFR vs Sf/Ss 65.4 4.8 −0.002 0.62 −0.019 0.970
SE standard error, e-CC estimated creatinine clearance based on Cockcroft-Gault equation, e-GFR estimated glomerular filtration rate according to
the abbreviated Modification of Diet in Renal Disease (MDRD) equation, Sf slope of the accelerated (fast: f) part of the blood activity clearance
curve, Ss slope of the slower (s) part of blood activity clearance curve
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